Thomas Muster obtained his PhD in Biotechnology from the University of Natural Resources and Applied Life Sciences in Vienna and is Professor for Virology. He contributed to numerous key inventions in vaccine development such as the discovery of a conserved antigen on HIV, a melanoma-associated retrovirus and the interferon antagonist NS1 of influenza virus. Dr. Muster also co-authored more than 50 publications in the field of virology and cancer. He co-founded AVIR Green Hills Biotechnology AG where he was CEO/CSO and successfully steered the live attenuated influenza vaccine deltaFLU all the way from discovery through to clinical phase II. He is CSO and Managing Director of Vivaldi AG and co-founder and CEO of Blue Sky Vaccines. Also a co-founder and board member of Nuvonis, Thomas is supporting the management in comprising intellectual property as well as technology and business development.